1 comment

sorted by: hot top controversial new old
[–] 8 points 5 days ago

The treatment failed to show a statistically significant improvement in overall survival (OS) in patients with previously treated, EGFR-mutated non-small cell lung cancer (NSCLC).

A drug not doing what they claimed seems to be a good reason not to approve it for the purpose they are filing for, doesn't it?

Summit already telegraphed the negative survival result in May.

the presentation at WCLC confirms that HARMONi missed OS at its final analysis.

The final OS analysis was triggered by 261 deaths in the 438-person trial. At that time, 122 patients (56%) in the ivonescimab-chemo arm and 140 (64%) in the chemo group had died. The median OS was 16.8 months and 14 months, respectively.

Missing OS was particularly bad for ivonescimab because the FDA has told Summit that a statistically significant OS benefit is necessary to support an approval in second-line EGFR-mutated NSCLC.

Doesn't seem like it actually helped cancer patients is kind of the problem here, wall street bets are irrelevant.

  • source